Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Aligned with the U.S. Food ...

Nkarta restructures to extend its cash runway into 2029, with upcoming NKX019 clinical data readouts in H2 2025. Analysts ...

Nkarta is laying off a third of its employees, including half of the biotech’s executive leadership, as the company diverts ...

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimm ...

Exclusive: Usain Bolt’s 9.58-second world record could be under threat if technology endorsed by a British Olympian gets the go-ahead ...